End-stage heart failure patients, especially female patients, could have a new lease of life as a French artificial heart manufacturer Car carpet announced Tuesday that she had successfully implanted her artificial heart Aeson in the chest cavity of a 57-year-old woman.
“This 3rd implant in the United States was a milestone not only because it allowed us to finalize the recruitment of the first cohort of EFS patients, but above all because it is the first time that our device helps a woman with heart failure. This achievement confirms that height limitations for adults are minimal, making us very confident in Aeson’s potential to become a therapy of choice for a large patient population, ”said Stéphane Piat, CEO of Carmat.
What once seemed like science fiction now seems to border on reality. Cases like this point to the future, where bioprosthetic hearts could one day be a therapeutic alternative for patients with end-stage biventricular heart failure.
Paris-based Carmat is developing what it says is the world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulating. The company implanted the first Aeson artificial heart in its US-based clinical trial of July 15th at Duke University Hospital. Today’s recipient is the third person and the first woman to receive what the company calls the world’s most advanced total artificial heart. The implantation was performed by a team of surgeons led by Dr. Mark S. Slaughter, professor and chair of the Department of Cardiovascular and Thoracic Surgery at the University of Louisville and UofL physician at the Jewish Hospital in Louisville, Ky.
The primary endpoint of the study is survival of the patient 180 days after implantation or successful heart transplantation within 180 days of implantation. In total, 10 patients eligible for the transplant are expected be registered for the trial.
Carmat’s ultimate goal is not only to save time, but also to make Aeson the premier alternative to a heart transplant, noting that these can be difficult to find due to a lack of human transplants. available.
Slaughter also spoke about the importance of today’s step.
“The Aeson artificial heart is compact enough to fit in smaller chest cavities, which are more commonly found in women, giving hope to a wider variety of men and women waiting for. a heart transplant and increases the chances of success, ”he said, adding that his department continues to be impressed with the performance of the device.
Bioprosthetics offer patients awaiting heart transplants a better quality of life. The Aeson weighs 4 kilograms and is powered by two batteries which provide approximately four hours of charging time before needing to be connected to a main power supply. It consists of sensors that detect blood pressure, thus allowing an algorithm to monitor blood flow in real time.
In December 2020, Carmat received a CE marking for Aeson, allowing the company to market it in the EU as a gateway to a transplant. The only artificial heart approved for use in the United States is SynCardia‘s Temporary total artificial heart (TAH), which has a “fixed beat” rather than autonomously adapting to the patient’s physical activity.
IDTechEx market research firm projects that the cardiovascular disease technology market will be worth more than $ 40 billion by 2030.